Search Edit My Profile Login to Profiles FAQs / About
Thomas Loughran
Title Professor Of Medicine; Director Of Penn State Cancer Institute
Institution College of Medicine
Department Medicine
Division Hematology Oncology
Address 500 University Drive Hershey PA 17033
Telephone 7175314034
Email
Background
PREFERRED TITLE/ROLE:

Physician, Director of Penn State Cancer Institute, Professor of Medicine

EDUCATION:

Fellowship, Medical Oncology, Fred Hutchinson Cancer Research Center (1985)
Residency, Internal Medicine, Thomas Jefferson University Hospital (1982)
Internship, Internal Medicine, Thomas Jefferson University Hospital (1980)
M.D., Hahnemann University (1979)

NARRATIVE:

Upon completing his Biology degree at Ursinus College in 1975, Dr. Thomas Loughran continued on to Hahnemann Medical School where he earned his medical degree, graduating in 1979. He then pursued both his internship and residency at Thomas Jefferson University Hospital, followed by a successful fellowship at the Fred Hutchinson Cancer Research Center at the University of Washington.

Throughout the 80’s and early 90’s, Dr. Loughran worked in the Clinical Research Division at the Fred Hutchinson Cancer Research Center under the leadership of Nobel Laureate, Dr. E.D. Thomas. He then returned back east and spent time as a professor of medicine and Associate Director of the Bone Marrow Transplant Program at the SUNY Health Science Center, and Chief of Hematology at the Veteran's Administration Medical Center in Syracuse, New York. He then went on to become the Program Leader of Hematologic Malignancies at the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida in Tampa. Dr. Loughran is the first Director of the Penn State Hershey Cancer Institute, appointed in 2003.

Dr. Loughran was instrumental in discovering a new hematologic malignancy which he termed large granular lymphocyte (LGL) leukemia. Dr. Loughran’s career path has been a testament to translational research – with his clinical observations leading to discoveries in the laboratory, and his laboratory research contributing to improved clinical treatments. Dr. Loughran has had continuous funding for his research since his fellowship in 1985.
Publications
1. Steinway SN, Loughran TP. Targeting IL-15 in large granular lymphocyte leukemia. Expert Rev Clin Immunol. 2013 May; 9(5):405-8.
  View in: PubMed
 
2. Leblanc FR, Hasanali ZS, Loughran TP. Does IL-15 have a causative role in large granular lymphocyte leukemia? Immunotherapy. 2013 Mar; 5(3):231-4.
  View in: PubMed
 
3. Shah MV, Barochia A, Loughran TP. Impact of genetic targets on cancer therapy in acute myelogenous leukemia. Adv Exp Med Biol. 2013; 779:405-37.
  View in: PubMed
 
4. Watters RJ, Loughran TP. Diagnosing large granular lymphocyte leukemia is bloody difficult. Leuk Lymphoma. 2013 Feb; 54(2):438-9.
  View in: PubMed
 
5. Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 2013 Apr; 27(4):897-906.
  View in: PubMed
 
6. Ren T, Dong W, Takahashi Y, Xiang D, Yuan Y, Liu X, Loughran TP, Sun SC, Wang HG, Cheng H. HTLV-2 Tax immortalizes human CD4+ memory T lymphocytes by oncogenic activation and dysregulation of autophagy. J Biol Chem. 2012 Oct 5; 287(41):34683-93.
  View in: PubMed
 
7. Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol. 2012 Sep 15; 189(6):3198-208.
  View in: PubMed
 
8. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-Segui I, Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, Wlodarski MW, Porkka K, Sekeres MA, List A, Mustjoki S, Loughran TP, Maciejewski JP. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012 Oct 11; 120(15):3048-57.
  View in: PubMed
 
9. Leblanc F, Zhang D, Liu X, Loughran TP. Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol. 2012 Jul; 8(7):787-801.
  View in: PubMed
 
10. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP, Heckman CA, Maciejewski JP, Mustjoki S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012 May 17; 366(20):1905-13.
  View in: PubMed
 
11. Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res. 2012 May; 36(5):581-7.
  View in: PubMed
 
12. Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, Amin S, Cheng C, Qin Y, Schonbrunn E, Daughdrill G, Loughran TP, Sebti S, Wang HG. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem. 2012 Mar 23; 287(13):10224-35.
  View in: PubMed
 
13. Watters RJ, Kester M, Tran MA, Loughran TP, Liu X. Development and use of ceramide nanoliposomes in cancer. Methods Enzymol. 2012; 508:89-108.
  View in: PubMed
 
14. Zhang D, Loughran TP. Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology Am Soc Hematol Educ Program. 2012; 2012:652-9.
  View in: PubMed
 
15. Saadatpour A, Wang RS, Liao A, Liu X, Loughran TP, Albert I, Albert R. Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia. PLoS Comput Biol. 2011 Nov; 7(11):e1002267.
  View in: PubMed
 
16. Watters RJ, Wang HG, Sung SS, Loughran TP, Liu X. Targeting sphingosine-1-phosphate receptors in cancer. Anticancer Agents Med Chem. 2011 Nov; 11(9):810-7.
  View in: PubMed
 
17. Loughran TP, Wang HG. Editorial [hot topic: Therapeutic targeting of the sphingolipid "biostat" in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang)]. Anticancer Agents Med Chem. 2011 Nov; 11(9):780-1.
  View in: PubMed
 
18. El-Bayoumy K, Das A, Russell S, Wolfe S, Jordan R, Renganathan K, Loughran TP, Somiari R. The effect of selenium enrichment on baker's yeast proteome. J Proteomics. 2012 Jan 4; 75(3):1018-30.
  View in: PubMed
 
19. Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother. 2012 Apr; 61(4):523-33.
  View in: PubMed
 
20. Clemente MJ, Wlodarski MW, Makishima H, Viny AD, Bretschneider I, Shaik M, Bejanyan N, Lichtin AE, His ED, Paquette RL, Loughran TP, Maciejewski JP. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011 Oct 20; 118(16):4384-93.
  View in: PubMed
 
21. Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV, Zhang LQ, Li Y, Ryland L, Yang J, Aliaga C, Dewey A, Rogers A, Loughran K, Hirsch L, Jarbadan NR, Baab KT, Liao J, Wang HG, Kester M, Desai D, Amin S, Loughran TP, Liu X. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood. 2011 Sep 8; 118(10):2793-800.
  View in: PubMed
 
22. Watters RJ, Liu X, Loughran TP. T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias. Leuk Lymphoma. 2011 Dec; 52(12):2217-25.
  View in: PubMed
 
23. Campbell C, Zhang R, Haley JS, Liu X, Loughran T, Schell TD, Albert R, Thakar J. Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach. Front Physiol. 2011; 2:32.
  View in: PubMed
 
24. Barth BM, I Altinoglu E, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH, Loughran TP, Claxton DF, Kester M. Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano. 2011 Jul 26; 5(7):5325-37.
  View in: PubMed
 
25. Liu X, Loughran TP. The spectrum of large granular lymphocyte leukemia and Felty's syndrome. Curr Opin Hematol. 2011 Jul; 18(4):254-9.
  View in: PubMed
 
26. Yang J, Loughran TP. Potential clinical application of imatinib mesylate in patients with leukemic large granular lymphocytes. Leuk Lymphoma. 2011 Oct; 52(10):1834-5.
  View in: PubMed
 
27. Yu J, Mitsui T, Wei M, Mao H, Butchar JP, Shah MV, Zhang J, Mishra A, Alvarez-Breckenridge C, Liu X, Liu S, Yokohama A, Trotta R, Marcucci G, Benson DM, Loughran TP, Tridandapani S, Caligiuri MA. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J Clin Invest. 2011 Apr; 121(4):1456-70.
  View in: PubMed
 
28. Zhang R, Loughran TP. Off-target effects of tyrosine kinase inhibitors: Beauty or the Beast? Leuk Lymphoma. 2011 Apr; 52(4):556-7.
  View in: PubMed
 
29. Ryland LK, Fox TE, Liu X, Loughran TP, Kester M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther. 2011 Jan 15; 11(2):138-49.
  View in: PubMed
 
30. Takahashi Y, Meyerkord CL, Hori T, Runkle K, Fox TE, Kester M, Loughran TP, Wang HG. Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. Autophagy. 2011 Jan; 7(1):61-73.
  View in: PubMed
 
31. Lamy T, Loughran TP. How I treat LGL leukemia. Blood. 2011 Mar 10; 117(10):2764-74.
  View in: PubMed
 
32. Talamo G, Farooq U, Zangari M, Liao J, Dolloff NG, Loughran TP, Epner E. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):464-8.
  View in: PubMed
 
33. Iqbal J, Weisenburger DD, Chowdhury A, Tsai MY, Srivastava G, Greiner TC, Kucuk C, Deffenbacher K, Vose J, Smith L, Au WY, Nakamura S, Seto M, Delabie J, Berger F, Loong F, Ko YH, Sng I, Liu X, Loughran TP, Armitage J, Chan WC. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic ?d T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia. 2011 Feb; 25(2):348-58.
  View in: PubMed
 
34. Zhang R, Shah MV, Loughran TP. The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol. 2010 Sep; 28(3):105-17.
  View in: PubMed
 
35. Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan SF, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, Zhang R, Liao J, Sayers TJ, Kester M, Loughran TP. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood. 2010 Nov 18; 116(20):4192-201.
  View in: PubMed
 
36. Epling-Burnette PK, Loughran TP. Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opin Investig Drugs. 2010 May; 19(5):689-98.
  View in: PubMed
 
37. Wozney JL, Damluji AA, Ahmed F, Zangari M, Loughran TP, Talamo G. Estimation of daily proteinuria in patients with multiple myeloma by using the protein-to-creatinine ratio in random urine samples. Acta Haematol. 2010; 123(4):226-9.
  View in: PubMed
 
38. Abbi KK, Rizvi SM, Sivik J, Thyagarajan S, Loughran T, Drabick JJ. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature. Leuk Res. 2010 Jul; 34(7):e154-6.
  View in: PubMed
 
39. Talamo G, Barochia A, Zangari M, Loughran TP. Multiple myeloma presenting as CEA-producing rectal cancer. Rare Tumors. 2010; 2(1):e4.
  View in: PubMed
 
40. Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Ganetsky R, Latham D, Paulic K, Afable M, Saba HI, Loughran TP, Maciejewski JP. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol. 2010 May 1; 28(13):2253-8.
  View in: PubMed
 
41. Pastor DM, Eggers AD, Drabick JJ, Loughran TP, Bayerl MG, Shope TR. Retroperitoneal diffuse large B-cell lymphoma presenting as pseudoachalasia. J Clin Oncol. 2010 Apr 20; 28(12):e184-7.
  View in: PubMed
 
42. Thomas A, Perzova R, Abbott L, Benz P, Poiesz MJ, Dube S, Loughran T, Ferrer J, Sheremata W, Glaser J, Leon-Ponte M, Poiesz BJ. LGL leukemia and HTLV. AIDS Res Hum Retroviruses. 2010 Jan; 26(1):33-40.
  View in: PubMed
 
43. Yang J, Liu X, Nyland SB, Zhang R, Ryland LK, Broeg K, Baab KT, Jarbadan NR, Irby R, Loughran TP. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood. 2010 Jan 7; 115(1):51-60.
  View in: PubMed
 
44. Hodge DL, Yang J, Buschman MD, Schaughency PM, Dang H, Bere W, Yang Y, Savan R, Subleski JJ, Yin XM, Loughran TP, Young HA. Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res. 2009 May 1; 69(9):3986-94.
  View in: PubMed
 
45. Nyland SB, Loughran TP. Putting HIV-1 apoptosis mediators to work against cancer: a killer job, with benefits. Cancer Biol Ther. 2009 Jan; 8(2):188-91.
  View in: PubMed
 
46. Shah MV, Zhang R, Loughran TP. Never say die: survival signaling in large granular lymphocyte leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S244-53.
  View in: PubMed
 
47. Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood. 2009 Apr 2; 113(14):3226-34.
  View in: PubMed
 
48. Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, Albert R, Loughran TP. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A. 2008 Oct 21; 105(42):16308-13.
  View in: PubMed
 
49. Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Wei S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 2008 Dec 1; 112(12):4694-8.
  View in: PubMed
 
50. Shah MV, Zhang R, Irby R, Kothapalli R, Liu X, Arrington T, Frank B, Lee NH, Loughran TP. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood. 2008 Aug 1; 112(3):770-81.
  View in: PubMed
 
51. Viny AD, Lichtin A, Pohlman B, Loughran T, Maciejewski J. Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia. Leuk Lymphoma. 2008 May; 49(5):932-8.
  View in: PubMed
 
52. Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F, Wei S, Loughran TP. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood. 2008 Feb 1; 111(3):1610-6.
  View in: PubMed
 
53. Lai DW, Loughran TP, Maciejewski JP, Sasu S, Song SX, Epling-Burnette PK, Paquette RL. Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. Leuk Res. 2008 May; 32(5):823-7.
  View in: PubMed
 
54. Sokol L, Loughran TP. Large granular lymphocyte leukemia. Curr Hematol Malig Rep. 2007 Oct; 2(4):278-82.
  View in: PubMed
 
55. Bourgault-Rouxel AS, Loughran TP, Zambello R, Epling-Burnette PK, Semenzato G, Donadieu J, Amiot L, Fest T, Lamy T. Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases. Leuk Res. 2008 Jan; 32(1):45-8.
  View in: PubMed
 
56. Thomas J, Haseman JK, Goodman JI, Ward JM, Loughran TP, Spencer PJ. A review of large granular lymphocytic leukemia in Fischer 344 rats as an initial step toward evaluating the implication of the endpoint to human cancer risk assessment. Toxicol Sci. 2007 Sep; 99(1):3-19.
  View in: PubMed
 
57. Burks EJ, Loughran TP. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006 Sep; 20(5):245-66.
  View in: PubMed
 
58. Sokol L, Loughran TP. Large granular lymphocyte leukemia. Oncologist. 2006 Mar; 11(3):263-73.
  View in: PubMed
 
59. Hellmich B, Pinals RS, Loughran TP, Sullivan KE. New clues to accrue on neutropenia in rheumatoid arthritis. Clin Immunol. 2005 Oct; 117(1):1-5.
  View in: PubMed
 
60. Wlodarski MW, O'Keefe C, Howe EC, Risitano AM, Rodriguez A, Warshawsky I, Loughran TP, Maciejewski JP. Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood. 2005 Oct 15; 106(8):2769-80.
  View in: PubMed
 
61. Burks EJ, Loughran TP. Perspectives in the treatment of LGL leukemia. Leuk Res. 2005 Feb; 29(2):123-5.
  View in: PubMed
 
62. Kothapalli R, Nyland SB, Kusmartseva I, Bailey RD, McKeown TM, Loughran TP. Constitutive production of proinflammatory cytokines RANTES, MIP-1beta and IL-18 characterizes LGL leukemia. Int J Oncol. 2005 Feb; 26(2):529-35.
  View in: PubMed
 
63. Epling-Burnette PK, Bai F, Wei S, Chaurasia P, Painter JS, Olashaw N, Hamilton A, Sebti S, Djeu JY, Loughran TP. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene. 2004 Dec 9; 23(57):9220-9.
  View in: PubMed
 
64. Sokol L, Agrawal D, Loughran TP. Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia. Leuk Res. 2005 Apr; 29(4):381-7.
  View in: PubMed
 
65. Epling-Burnette PK, Painter JS, Chaurasia P, Bai F, Wei S, Djeu JY, Loughran TP. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood. 2004 May 1; 103(9):3431-9.
  View in: PubMed
 
66. Berliner N, Horwitz M, Loughran TP. Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program. 2004; 63-79.
  View in: PubMed
 
67. Mohapatra S, Chu B, Wei S, Djeu J, Epling-Burnette PK, Loughran T, Jove R, Pledger WJ. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res. 2003 Dec 1; 63(23):8523-30.
  View in: PubMed
 
68. Kothapalli R, Yoder SJ, Kusmartseva I, Loughran TP. Characterization of a variant of PAC-1 in large granular lymphocyte leukemia. Protein Expr Purif. 2003 Nov; 32(1):52-60.
  View in: PubMed
 
69. Sokol L, Loughran TP. Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas. Curr Treat Options Oncol. 2003 Aug; 4(4):289-96.
  View in: PubMed
 
70. Lamy T, Loughran TP. Clinical features of large granular lymphocyte leukemia. Semin Hematol. 2003 Jul; 40(3):185-95.
  View in: PubMed
 
71. Epling-Burnette PK, Loughran TP. Survival signals in leukemic large granular lymphocytes. Semin Hematol. 2003 Jul; 40(3):213-20.
  View in: PubMed
 
72. Kothapalli R, Danyluck GM, Bailey RD, Loughran TP. Problems associated with product enhancement reverse transcriptase assay using bacteriophage MS2 RNA as a template. J Virol Methods. 2003 May; 109(2):203-7.
  View in: PubMed
 
73. Nyland SB, Cao C, Bai Y, Loughran TP, Ugen KE. Modulation of infection and type 1 cytokine expression parameters by morphine during in vitro coinfection with human T-cell leukemia virus type I and HIV-1. J Acquir Immune Defic Syndr. 2003 Apr 1; 32(4):406-16.
  View in: PubMed
 
74. Kanchan K, Loughran TP. Antigen-driven clonal T cell expansion in disorders of hematopoiesis. Leuk Res. 2003 Apr; 27(4):291-2.
  View in: PubMed
 
75. Yang J, Fier A, Carter Y, Liu G, Epling-Burnette PK, Bai F, Loughran TP, Mastorides S, Norman JG, Murr MM. Liver injury during acute pancreatitis: the role of pancreatitis-associated ascitic fluid (PAAF), p38-MAPK, and caspase-3 in inducing hepatocyte apoptosis. J Gastrointest Surg. 2003 Feb; 7(2):200-7; discussion 208.
  View in: PubMed
 
76. Kothapalli R, Bailey RD, Kusmartseva I, Mane S, Epling-Burnette PK, Loughran TP. Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol. 2003 Jan; 22(1):33-9.
  View in: PubMed
 
77. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002 Dec 12; 21(57):8804-16.
  View in: PubMed
 
78. Kothapalli R, Kusmartseva I, Loughran TP. Characterization of a human sphingosine-1-phosphate receptor gene (S1P5) and its differential expression in LGL leukemia. Biochim Biophys Acta. 2002 Dec 12; 1579(2-3):117-23.
  View in: PubMed
 
79. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2002 Oct 15; 62(20):5761-9.
  View in: PubMed
 
80. Kothapalli R, Yoder SJ, Mane S, Loughran TP. Microarray results: how accurate are they? BMC Bioinformatics. 2002 Aug 23; 3:22.
  View in: PubMed
 
81. Liu JH, Wei S, Lamy T, Li Y, Epling-Burnette PK, Djeu JY, Loughran TP. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood. 2002 Aug 15; 100(4):1449-53.
  View in: PubMed
 
82. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T. Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol. 2002 Aug 1; 20(15):3249-53.
  View in: PubMed
 
83. Epling-Burnette PK, Garcia R, Bai F, Ismail S, Loughran TP, Djeu JY, Jove R, Wei S. Carboxy-terminal truncated STAT5 is induced by interleukin-2 and GM-CSF in human neutrophils. Cell Immunol. 2002 May-Jun; 217(1-2):1-11.
  View in: PubMed
 
84. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28; 346(9):645-52.
  View in: PubMed
 
85. Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bailey RD, Garcia R, Jove R, Djeu JY, Loughran TP, Wei S. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol. 2001 Jun 15; 166(12):7486-95.
  View in: PubMed
 
86. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001 Feb; 107(3):351-62.
  View in: PubMed
 
87. Greer JP, Kinney MC, Loughran TP. T cell and NK cell lymphoproliferative disorders. Hematology Am Soc Hematol Educ Program. 2001; 259-81.
  View in: PubMed
 
88. Liu JH, Wei S, Lamy T, Epling-Burnette PK, Starkebaum G, Djeu JY, Loughran TP. Chronic neutropenia mediated by fas ligand. Blood. 2000 May 15; 95(10):3219-22.
  View in: PubMed
 
89. Coakley G, Brooks D, Iqbal M, Kondeatis E, Vaughan R, Loughran TP, Panayi GS, Lanchbury JS. Major histocompatility complex haplotypic associations in Felty's syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1 *0401. Rheumatology (Oxford). 2000 Apr; 39(4):393-8.
  View in: PubMed
 
90. Perzova RN, Loughran TP, Dube S, Ferrer J, Esteban E, Poiesz BJ. Lack of BLV and PTLV DNA sequences in the majority of patients with large granular lymphocyte leukaemia. Br J Haematol. 2000 Apr; 109(1):64-70.
  View in: PubMed
 
91. Lesesve JF, Feugier P, Lamy T, Béné MC, Grégoire MJ, Lenormand B, Loughran T. Association of B-chronic lymphocytic leukaemia and T-large granular lymphocyte leukaemia. Clin Lab Haematol. 2000 Apr; 22(2):121-2.
  View in: PubMed
 
92. Lamy T, Bauer FA, Liu JH, Li YX, Pillemer E, Shahidi H, Gregory SA, Zambello R, Marcolongo R, Semenzato G, Loughran TP. Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. Br J Haematol. 2000 Mar; 108(4):717-23.
  View in: PubMed
 
93. Hall MA, McGlinn E, Coakley G, Fisher SA, Boki K, Middleton D, Kaklamani E, Moutsopoulos H, Loughran TP, Ollier WE, Panayi GS, Lanchbury JS. Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun. 2000 Feb; 1(3):219-24.
  View in: PubMed
 
94. Lamy T, Loughran TP. Current concepts: large granular lymphocyte leukemia. Blood Rev. 1999 Dec; 13(4):230-40.
  View in: PubMed
 
95. Coakley G, Manolios N, Loughran TP, Panayi GS, Lanchbury JS. A Fas promoter polymorphism at position -670 in the enhancer region does not confer susceptibility to Felty's and large granular lymphocyte syndromes. Rheumatology (Oxford). 1999 Sep; 38(9):883-6.
  View in: PubMed
 
96. Loughran TP. CD56+ hematologic malignancies. Leuk Res. 1999 Jul; 23(7):675-6.
  View in: PubMed
 
97. Lamy T, Liu JH, Landowski TH, Dalton WS, Loughran TP. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood. 1998 Dec 15; 92(12):4771-7.
  View in: PubMed
 
98. Gentile TC, Hadlock KG, Uner AH, Delal B, Squiers E, Crowley S, Woodman RC, Foung SK, Poiesz BJ, Loughran TP. Large granular lymphocyte leukaemia occurring after renal transplantation. Br J Haematol. 1998 Jun; 101(3):507-12.
  View in: PubMed
 
99. Love JL, Marchioli CC, Dube S, Bryz-Gornia V, Loughran TP, Glaser JB, Esteban E, Feldman L, Ferrer JF, Poiesz BJ. Expansion of clonotypic T-cell populations in the peripheral blood of asymptomatic Gran Chaco Amerindians infected with HTLV-IIB. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jun 1; 18(2):178-85.
  View in: PubMed
 
100. Loughran TP. Large granular lymphocytic leukemia: an overview. Hosp Pract (Minneap). 1998 May 15; 33(5):133-8.
  View in: PubMed
 
101. Loughran TP, Hadlock KG, Perzova R, Gentile TC, Yang Q, Foung SK, Poiesz BJ. Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia. Br J Haematol. 1998 May; 101(2):318-24.
  View in: PubMed
 
102. Lamy T, Drenou B, Fardel O, Amiot L, Grulois I, Le Prise PY, Loughran TP, Fauchet R. Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes. Br J Haematol. 1998 Mar; 100(3):509-15.
  View in: PubMed
 
103. Loughran TP, Hadlock KG, Yang Q, Perzova R, Zambello R, Semenzato G, Foung SK, Poiesz BJ. Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes. Blood. 1997 Sep 1; 90(5):1977-81.
  View in: PubMed
 
104. Loughran TP, Abbott L, Gentile TC, Love J, Cunningham C, Friedman-Kien A, Huang YQ, Poiesz BJ. Absence of human herpes virus 8 DNA sequences in large granular lymphocyte (LGL) leukemia. Leuk Lymphoma. 1997 Jun; 26(1-2):177-80.
  View in: PubMed
 
105. Starkebaum G, Loughran TP, Gaur LK, Davis P, Nepom BS. Immunogenetic similarities between patients with Felty's syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1997 Apr; 40(4):624-6.
  View in: PubMed
 
106. Perzova R, Loughran TP. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Br J Haematol. 1997 Apr; 97(1):123-6.
  View in: PubMed
 
107. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997 Jan 1; 89(1):256-60.
  View in: PubMed
 
108. Gentile TC, Wener MH, Starkebaum G, Loughran TP. Humoral immune abnormalities in T-cell large granular lymphocyte leukemia. Leuk Lymphoma. 1996 Oct; 23(3-4):365-70.
  View in: PubMed
 
109. Pellenz M, Zambello R, Semenzato G, Loughran TP. Detection of Epstein-Barr virus by PCR analyses in lymphoproliferative disease of granular lymphocytes. Leuk Lymphoma. 1996 Oct; 23(3-4):371-4.
  View in: PubMed
 
110. Gentile TC, Loughran TP. Resolution of autoimmune hemolytic anemia following splenectomy in CD3+ large granular lymphocyte leukemia. Leuk Lymphoma. 1996 Oct; 23(3-4):405-8.
  View in: PubMed
 
111. Loughran TP. HTLV infection and hematologic malignancies. Leuk Res. 1996 Jun; 20(6):457-8.
  View in: PubMed
 
112. Starkebaum G, Shasteen NM, Fleming-Jones RM, Loughran TP, Mannik M. Sera of patients with rheumatoid arthritis contain antibodies to recombinant human T-lymphotrophic virus type I/II envelope glycoprotein p21. Clin Immunol Immunopathol. 1996 May; 79(2):182-8.
  View in: PubMed
 
113. Kingreen D, Dalal BI, Heyman M, Phillips GL, Horsman D, Kidd P, Loughran TP. Lymphocytosis of large granular lymphocytes in patients with Hodgkin's disease. Am J Hematol. 1995 Dec; 50(4):234-6.
  View in: PubMed
 
114. Gentile TC, Loughran TP. Interleukin-12 is a costimulatory cytokine for leukemic CD3+ large granular lymphocytes. Cell Immunol. 1995 Nov; 166(1):158-61.
  View in: PubMed
 
115. Zambello R, Loughran TP, Trentin L, Pontisso P, Battistella L, Raimondi R, Facco M, Sancetta R, Agostini C, Pizzolo G, et al. Serologic and molecular evidence for a possible pathogenetic role of viral infection in CD3-negative natural killer-type lymphoproliferative disease of granular lymphocytes. Leukemia. 1995 Jul; 9(7):1207-11.
  View in: PubMed
 
116. Brody JP, Allen S, Schulman P, Sun T, Chan WC, Friedman HD, Teichberg S, Koduru P, Cone RW, Loughran TP. Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents. Cancer. 1995 May 15; 75(10):2474-83.
  View in: PubMed
 
117. Litam PP, Loughran TP. Recurrent infection in a patient with chronic neutropenia. Hosp Pract (Off Ed). 1995 Feb 15; 30(2):117-8.
  View in: PubMed
 
118. Davey MP, Starkebaum G, Loughran TP. CD3+ leukemic large granular lymphocytes utilize diverse T-cell receptor V beta genes. Blood. 1995 Jan 1; 85(1):146-50.
  View in: PubMed
 
119. Litam PP, Loughran TP. Clostridium septicum bacteremia in a patient with large granular lymphocyte leukemia. Cancer Invest. 1995; 13(5):492-4.
  View in: PubMed
 
120. Loughran TP, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood. 1994 Oct 1; 84(7):2164-70.
  View in: PubMed
 
121. Gentile TC, Uner AH, Hutchison RE, Wright J, Ben-Ezra J, Russell EC, Loughran TP. CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia. Blood. 1994 Oct 1; 84(7):2315-21.
  View in: PubMed
 
122. Loughran TP, Sherman MP, Ruscetti FW, Frey S, Coyle T, Montagna RA, Jones B, Starkebaum G, Poiesz BJ. Prototypical HTLV-I/II infection is rare in LGL leukemia. Leuk Res. 1994 Jun; 18(6):423-9.
  View in: PubMed
 
123. Loughran TP. Clonal diseases of large granular lymphocytes. Blood. 1993 Jul 1; 82(1):1-14.
  View in: PubMed
 
124. Loughran TP, Zambello R, Ashley R, Guderian J, Pellenz M, Semenzato G, Starkebaum G. Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood. 1993 May 15; 81(10):2723-7.
  View in: PubMed
 
125. Nash R, McSweeney P, Zambello R, Semenzato G, Loughran TP. Clonal studies of CD3- lymphoproliferative disease of granular lymphocytes. Blood. 1993 May 1; 81(9):2363-8.
  View in: PubMed
 
126. Loughran TP, Coyle T, Sherman MP, Starkebaum G, Ehrlich GD, Ruscetti FW, Poiesz BJ. Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia. Blood. 1992 Sep 1; 80(5):1116-9.
  View in: PubMed
 
127. Riddell SR, Greenberg PD, Overell RW, Loughran TP, Gilbert MJ, Lupton SD, Agosti J, Scheeler S, Coombs RW, Corey L. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum Gene Ther. 1992 Jun; 3(3):319-38.
  View in: PubMed
 
128. Aprile JA, Russo M, Pepe MS, Loughran TP. Activation signals leading to proliferation of normal and leukemic CD3+ large granular lymphocytes. Blood. 1991 Sep 1; 78(5):1282-5.
  View in: PubMed
 
129. Storb R, Anasetti C, Appelbaum F, Bensinger W, Buckner CD, Clift R, Deeg HJ, Doney K, Hansen J, Loughran T, et al. Marrow transplantation for severe aplastic anemia and thalassemia major. Semin Hematol. 1991 Jul; 28(3):235-9.
  View in: PubMed
 
130. Yoon HJ, Aprile JA, Loughran TP. Interleukin-2 receptor monoclonal antibodies have no effect on anti-CD3 monoclonal antibody-mediated cytotoxicity in CD3+ leukemic large granular lymphocytes. Cell Immunol. 1990 Dec; 131(2):404-8.
  View in: PubMed
 
131. Yoon HJ, Sugamura K, Loughran TP. Activation of leukemic large granular lymphocytes by interleukin-2 via the p75 interleukin-2 receptor. Leukemia. 1990 Dec; 4(12):848-50.
  View in: PubMed
 
132. Loughran TP, Sullivan K, Morton T, Beckham C, Schubert M, Witherspoon R, Sale G, Sanders J, Fisher L, Shulman H, et al. Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990 Jul 1; 76(1):228-34.
  View in: PubMed
 
133. Loughran TP, Aprile JA, Ruscetti FW. Anti-CD3 monoclonal antibody-mediated cytotoxicity occurs through an interleukin-2-independent pathway in CD3+ large granular lymphocytes. Blood. 1990 Feb 15; 75(4):935-40.
  View in: PubMed
 
134. Pandolfi F, Loughran TP, Starkebaum G, Chisesi T, Barbui T, Chan WC, Brouet JC, De Rossi G, McKenna RW, Salsano F, et al. Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer. 1990 Jan 15; 65(2):341-8.
  View in: PubMed
 
135. Hanks GA, Mathews HH, Routson GW, Loughran TP. Supracondylar fracture of the femur following total knee arthroplasty. J Arthroplasty. 1989 Dec; 4(4):289-92.
  View in: PubMed
 
136. Agnarsson BA, Loughran TP, Starkebaum G, Kadin ME. The pathology of large granular lymphocyte leukemia. Hum Pathol. 1989 Jul; 20(7):643-51.
  View in: PubMed
 
137. Williams ML, Loughran TP, Kidd PG, Starkebaum GA. Polyclonal proliferation of activated suppressor/cytotoxic T cells with transient depression of natural killer cell function in acute infectious mononucleosis. Clin Exp Immunol. 1989 Jul; 77(1):71-6.
  View in: PubMed
 
138. Loughran TP, Starkebaum G, Ruscetti FW. Similar rearrangements of T-cell receptor beta gene in cell lines and uncultured cells from patients with large granular lymphocyte leukemia. Blood. 1988 Aug; 72(2):613-5.
  View in: PubMed
 
139. Loughran TP, Starkebaum G, Aprile JA. Rearrangement and expression of T-cell receptor genes in large granular lymphocyte leukemia. Blood. 1988 Mar; 71(3):822-4.
  View in: PubMed
 
140. Loughran TP, Starkebaum G, Kidd P, Neiman P. Clonal proliferation of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1988 Jan; 31(1):31-6.
  View in: PubMed
 
141. Loughran TP, Starkebaum G, Clark E, Wallace P, Kadin ME. Evaluation of splenectomy in large granular lymphocyte leukaemia. Br J Haematol. 1987 Oct; 67(2):135-40.
  View in: PubMed
 
142. Loughran TP, Starkebaum G. Large granular lymphocyte leukemia. Report of 38 cases and review of the literature. Medicine (Baltimore). 1987 Sep; 66(5):397-405.
  View in: PubMed
 
143. Loughran TP, Starkebaum G. Clinical features in large granular lymphocytic leukemia. Blood. 1987 Jun; 69(6):1786.
  View in: PubMed
 
144. Starkebaum G, Loughran TP, Kalyanaraman VS, Kadin ME, Kidd PG, Singer JW, Ruscetti FW. Serum reactivity to human T-cell leukaemia/lymphoma virus type I proteins in patients with large granular lymphocytic leukaemia. Lancet. 1987 Mar 14; 1(8533):596-9.
  View in: PubMed
 
145. Raff RF, Loughran TP, Deeg HJ, Aprile JA, Graham TC, Sale GE, Storb R. Role of radiation-resistant large granular lymphocytes in the rejection of unrelated DLA-nonidentical marrow grafts in dogs. Transplant Proc. 1987 Feb; 19(1 Pt 3):2718-20.
  View in: PubMed
 
146. Loughran TP, Draves KE, Starkebaum G, Kidd P, Clark EA. Induction of NK activity in large granular lymphocyte leukemia: activation with anti-CD3 monoclonal antibody and interleukin 2. Blood. 1987 Jan; 69(1):72-8.
  View in: PubMed
 
147. Loughran TP, Hammond WP. Adult-onset cyclic neutropenia is a benign neoplasm associated with clonal proliferation of large granular lymphocytes. J Exp Med. 1986 Dec 1; 164(6):2089-94.
  View in: PubMed
 
148. Loughran TP, Clark EA, Price TH, Hammond WP. Adult-onset cyclic neutropenia is associated with increased large granular lymphocytes. Blood. 1986 Nov; 68(5):1082-7.
  View in: PubMed
 
149. Raff RF, Deeg HJ, Loughran TP, Graham TC, Aprile JA, Sale GE, Storb R. Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donors. Blood. 1986 Oct; 68(4):861-8.
  View in: PubMed
 
150. Loughran TP, Deeg HJ, Storb R. Morphologic and phenotypic analysis of canine natural killer cells: evidence for T-cell lineage. Cell Immunol. 1985 Oct 15; 95(2):207-17.
  View in: PubMed
 
151. Wallis WJ, Loughran TP, Kadin ME, Clark EA, Starkebaum GA. Polyarthritis and neutropenia associated with circulating large granular lymphocytes. Ann Intern Med. 1985 Sep; 103(3):357-62.
  View in: PubMed
 
152. Loughran TP, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C, Lum LG, Slichter SJ. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985 Feb; 102(2):169-75.
  View in: PubMed
 
 
Keyword
Last Name
Institution
    
 
 
 
Co-Authors  
Kester, Mark
Liu, Xin
Nyland, Susan
Wang, Hong-gang
Yang, Jun
See all (26) people
Site Index | Privacy and Legal Statements | Copyright Information | The Pennsylvania State University © 2011